Business Wire

AlgaEnergy and Yokogawa Sign Strategic Partnership & Equity Agreement to Accelerate Growth of the Microalgae Biotech Sector

Del

AlgaEnergy, a Spanish biotechnology company specializing in the production and commercial applications of microalgae, and Yokogawa Electric Corporation (TOKYO:6841), a leading provider of industrial automation, control, and measurement technology, announce the signing of a partnership & equity participation agreement. The strategic agreement involves an approximately 10 million euro investment by Yokogawa to acquire newly issued shares of AlgaEnergy, making the Japanese company a reference shareholder.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181105006048/en/

AlgaEnergy's microalgae production facility in Cádiz, Spain (Photo: Business Wire)

AlgaEnergy's microalgae production facility in Cádiz, Spain (Photo: Business Wire)

Microalgae are a diverse group of unicellular photosynthetic micro-organisms that can thrive in a wide variety of aquatic habitats, such as oceans, lakes, and rivers. Their rapid rate of reproduction means they can be utilized effectively as a biological resource. They are recognized as having great potential to contribute to a more sustainable society through applications in diverse sectors ranging from agriculture, food, and animal feed through to pharmaceuticals, cosmetics, biomaterials and, in the future, sustainable biofuels.

AlgaEnergy has been a pioneer in the microalgae biotechnology field since 2007. It is currently operating a commercial production facility in the south of Spain, and, in late 2015, launched the world’s first line-up of microalgae-based biostimulant* products to promote efficient crop cultivation.

The entry of Yokogawa as a shareholder will enable AlgaEnergy to reinforce its position of international leadership, with the equity investment being used to fund a set of ambitious projects, including international expansion of its biostimulant product sales organization, entry into new sectors such as food and cosmetics, and development of its promising product pipeline.

However, the scope of the agreement extends beyond just financial investment. The two companies, which share strong synergies and a common vision, seek to build an industry-leading partnership in the microalgae biotechnology sector worldwide by collaborating in the areas of R&D, manufacturing, marketing, and sales. AlgaEnergy will leverage its broad knowledge and experience in the microalgae biological processes, accumulated throughout more than four decades of R&D by its scientific leader, the world-renowned microbiologist Professor Miguel Garcia Guerrero of the University of Seville. Yokogawa will provide the advanced technologies and knowhow related to automation of industrial processes that will be key for maximizing quality and efficiency as production volumes increase.

United by a commitment to sustainability

Augusto Rodríguez-Villa, AlgaEnergy’s president, highlighted that, “This agreement is the best possible partnership in the journey to achieve our mission to leverage the potential of microalgae worldwide. We share the same vision for the future, the belief that more sustainable development is possible and that microalgae can be a key contributor towards that objective.”

Tsuyoshi Abe, senior vice president and head of the Marketing Headquarters at Yokogawa, added, “Yokogawa aims to contribute directly to the UN’s Sustainable Development Goals through its core business activities, and this year we established a new Life Innovation business unit in line with that. This is our first serious foray into clean technology in the bioeconomy, which was recently added as a new focus area in our long-term business framework, so we have high expectations for this exciting strategic partnership.”

*  

Biostimulant: substance or micro-organisms whose function when applied to plants or the surrounding soil is to stimulate natural processes to enhance nutrient uptake, nutrient efficiency, tolerance to abiotic stress, and crop quality.

 

About AlgaEnergy

AlgaEnergy is a biotechnology company specialized in the science of microalgae. The company consolidates over four decades of state-of-the-art knowledge related to microalgae, generated by the main specialized universities, and has invested heavily in applied R&D, positioning itself as the main international reference in this field. AlgaEnergy’s mission is to develop and commercialize innovative, high-quality products derived from microalgae, targeting specific needs in different industries.
For more information about AlgaEnergy, please visit www.algaenergy.es/en/

About Yokogawa

Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 61 countries, generating US$3.8 billion in sales in FY2017.
For more information, please visit www.yokogawa.com.

The names of corporations, organizations, and products herein are either trademarks or registered trademarks of their respective holders.

Contact information

Yokogawa Electric Corporation
Philip Lewis
Public Relations Manager
Yokogawa-pr@cs.jp.yokogawa.com
2-9-32 Nakacho
Musashino-shi
Tokyo
Japan 180-8750
Tel: +81 422-52-5530
or
AlgaEnergy
Fernando Varés Orive
Communications Manager
fvo@algaenergy.es
Avenida de Europa, 19
Parque Empresarial “La Moraleja”
28108 Alcobendas, Madrid
Spain
Tel: +34 91-490-2020

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 14:33Pressemelding

Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W

Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 13:55Pressemelding

Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’

Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 13:15Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk

Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease16.11.2018 12:57Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, lumacaftor/ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF for patients aged 2 to 5 years old who have two copies of the F508del mutation. “Cystic fibrosis is a chronic, progressive disease and it is important to treat early to ensure the best possible outcomes for patients,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. “Today’s announcement brings us one step cl

Dimension Data Global Delivery Centre (GDC) in Prague wins the ABSL 2018 Diamond Award for Business Innovation16.11.2018 08:00Pressemelding

Dimension Data, the USD 8 billion global technology integrator and managed services provider, today announced that its Global Delivery Centre (GDC) in Prague has won the 2018 ABSL Diamond award for Business Innovation. The main purpose of this centre is to provide innovative, global service delivery capabilities and deep technical expertise to support our clients. The ABSL Diamond awards recognise companies that implement innovative projects, enhancing their business and strengthening the position of the business services sector. Every year, the aim is to identify successful activities in this sector and promote best practices, ultimately encouraging and inspiring others to follow suit. The ABSL celebrates initiatives that push business services forward and stand out as exemplary projects. Bill Padfield, Group Chief Operating Officer for Transformation and Services at Dimension Data, said: “Winning another award for our Support Services is a fantastic achievement. This time the ABSL Di

FCC Grants LeoSat U.S. Market Access16.11.2018 06:00Pressemelding

LeoSat Enterprises, the dynamic young company which is launching a unique new data network comprised of a constellation of up to 108 low-earth-orbit communications satellites, has been awarded the authority by the U.S. Federal Communications Commission (FCC) to provide NGSO (non-geostationary satellite orbit) services in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005890/en/ LeoSat's Global Business Backbone in Space (Graphic: Business Wire) The increasing demand for business connectivity and with it, the need to move large quantities of data quickly and securely around the world, is fast outpacing the infrastructure in place to carry it. Existing networks are already carrying more than 1 Zeta Byte of traffic globally and this is set to grow exponentially. The FCC market access grant will allow LeoSat to address currently unmet demand for high-bandwidth, low-latency, high-security data transmissio